InvestorsHub Logo
Followers 12
Posts 713
Boards Moderated 0
Alias Born 05/22/2012

Re: Blue Man post# 105060

Wednesday, 08/12/2020 4:18:52 PM

Wednesday, August 12, 2020 4:18:52 PM

Post# of 233523
It doesn't matter. Read up on multiplicity and alpha spend. This is why you cannot have statsig secondary end points w/o having statsig primary end points. From a statistical standpoint, on which is what the FDA relies, this was a FAIL and the drug would be rejected regardless of secondary endpoints. That is why there will be no emergency use approval
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News